Last reviewed · How we verify
Azithromycin Oral Liquid Product
Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.
Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Pharyngitis/tonsillitis.
At a glance
| Generic name | Azithromycin Oral Liquid Product |
|---|---|
| Also known as | Throza DPS |
| Sponsor | Copenhagen Studies on Asthma in Childhood |
| Drug class | Macrolide antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 2 |
Mechanism of action
This binding action prevents the translocation of peptides from the A site to the P site on the ribosome, effectively inhibiting the growth of bacteria. As a result, azithromycin is bacteriostatic against a wide range of Gram-positive and Gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Pharyngitis/tonsillitis
- Acute otitis media
- Skin/skin structure infections
- Lower respiratory tract infections
- Urogenital infections
- Pelvic inflammatory disease
- Mycoplasma pneumoniae infections
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Dizziness
- Fatigue
- Allergic reactions
- Hypersensitivity reactions
- Cardiovascular events
Key clinical trials
- Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms (PHASE2)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Early Life Interventions for Childhood Growth and Development In Tanzania (PHASE2, PHASE3)
- Treatment of Pediculosis (Head Lice) in Senegal (NA)
- Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides (PHASE1)
- Multiple Treatments for Ebola Virus Disease (EVD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: